{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T18:36:31Z","timestamp":1770489391921,"version":"3.49.0"},"reference-count":113,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T00:00:00Z","timestamp":1591228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-11-LABX-0018-01"],"award-info":[{"award-number":["ANR-11-LABX-0018-01"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-11-LABX-0016-01"],"award-info":[{"award-number":["ANR-11-LABX-0016-01"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-11-EQPX-0004"],"award-info":[{"award-number":["ANR-11-EQPX-0004"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Despite constant progress over the past three decades, multiple myeloma (MM) is still an incurable disease, and the identification of new biomarkers to better select patients and adapt therapy is more relevant than ever. Recently, the introduction of therapeutic monoclonal antibodies (mAbs) (including direct-targeting mAbs and immune checkpoint inhibitors) appears to have changed the paradigm of MM management, emphasizing the opportunity to cure MM patients through an immunotherapeutic approach. In this context, immuno-positron emission tomography (immunoPET), combining the high sensitivity and resolution of a PET camera with the specificity of a radiolabelled mAb, holds the capability to cement this new treatment paradigm for MM patients. It has the potential to non-invasively monitor the distribution of therapeutic antibodies or directly monitor biomarkers on MM cells, and to allow direct observation of potential changes over time and in response to various therapeutic interventions. Tumor response could, in the future, be anticipated more effectively to provide individualized treatment plans tailored to patients according to their unique imaging signatures. This work explores the important role played by immunotherapeutics in the management of MM, and focuses on some of the challenges for this drug class and the significant interest of companion imaging agents such as immunoPET.<\/jats:p>","DOI":"10.3390\/cancers12061467","type":"journal-article","created":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T03:32:21Z","timestamp":1591327941000},"page":"1467","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["ImmunoPET in Multiple Myeloma\u2014What? So What? Now What?"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8313-3287","authenticated-orcid":false,"given":"Cl\u00e9ment","family":"Bailly","sequence":"first","affiliation":[{"name":"CRCINA, INSERM, CNRS, Universit\u00e9 d\u2019Angers, Universit\u00e9 de Nantes, 44093 Nantes, France"},{"name":"Nuclear Medicine Department, University Hospital of Nantes, 44093 Nantes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Chalopin","sequence":"additional","affiliation":[{"name":"CRCINA, INSERM, CNRS, Universit\u00e9 d\u2019Angers, Universit\u00e9 de Nantes, 44093 Nantes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0973-5420","authenticated-orcid":false,"given":"S\u00e9bastien","family":"Gouard","sequence":"additional","affiliation":[{"name":"CRCINA, INSERM, CNRS, Universit\u00e9 d\u2019Angers, Universit\u00e9 de Nantes, 44093 Nantes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6932-7322","authenticated-orcid":false,"given":"Thomas","family":"Carlier","sequence":"additional","affiliation":[{"name":"CRCINA, INSERM, CNRS, Universit\u00e9 d\u2019Angers, Universit\u00e9 de Nantes, 44093 Nantes, France"},{"name":"Nuclear Medicine Department, University Hospital of Nantes, 44093 Nantes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Remaud-Le Sa\u00ebc","sequence":"additional","affiliation":[{"name":"CRCINA, INSERM, CNRS, Universit\u00e9 d\u2019Angers, Universit\u00e9 de Nantes, 44093 Nantes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5041-8531","authenticated-orcid":false,"given":"S\u00e9verine","family":"Marionneau-Lambot","sequence":"additional","affiliation":[{"name":"CRCINA, INSERM, CNRS, Universit\u00e9 d\u2019Angers, Universit\u00e9 de Nantes, 44093 Nantes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[{"name":"Department of Hematology, University Hospital of Nantes, 44093 Nantes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0275-2575","authenticated-orcid":false,"given":"Cyrille","family":"Touzeau","sequence":"additional","affiliation":[{"name":"Department of Hematology, University Hospital of Nantes, 44093 Nantes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7oise","family":"Kraeber-Bodere","sequence":"additional","affiliation":[{"name":"CRCINA, INSERM, CNRS, Universit\u00e9 d\u2019Angers, Universit\u00e9 de Nantes, 44093 Nantes, France"},{"name":"Nuclear Medicine Department, University Hospital of Nantes, 44093 Nantes, France"},{"name":"Nuclear Medicine Department, ICO-Ren\u00e9 Gauducheau Cancer Center, 44800 Saint-Herblain, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Bodet-Milin","sequence":"additional","affiliation":[{"name":"CRCINA, INSERM, CNRS, Universit\u00e9 d\u2019Angers, Universit\u00e9 de Nantes, 44093 Nantes, France"},{"name":"Nuclear Medicine Department, University Hospital of Nantes, 44093 Nantes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6347-6848","authenticated-orcid":false,"given":"Michel","family":"Ch\u00e9rel","sequence":"additional","affiliation":[{"name":"CRCINA, INSERM, CNRS, Universit\u00e9 d\u2019Angers, Universit\u00e9 de Nantes, 44093 Nantes, France"},{"name":"Nuclear Medicine Department, ICO-Ren\u00e9 Gauducheau Cancer Center, 44800 Saint-Herblain, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,6,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(14)60493-1","article-title":"Multiple myeloma","volume":"385","author":"Knop","year":"2015","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple myeloma epidemiology and survival: A unique malignancy","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Semin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"8039","DOI":"10.1200\/JCO.2019.37.15_suppl.8039","article-title":"Continued improvement in survival in multiple myeloma (MM) including high-risk patients","volume":"37","author":"Nandakumar","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"506","DOI":"10.3324\/haematol.2017.178103","article-title":"Outcome and survival of myeloma patients diagnosed 2008\u20132015. Real-world data on 4904 patients from the Swedish Myeloma Registry","volume":"103","author":"Blimark","year":"2017","journal-title":"Haematology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1200\/JOP.19.00244","article-title":"Current Treatment Strategies for Multiple Myeloma","volume":"16","author":"Branagan","year":"2020","journal-title":"JCO Oncol. Pr."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Bailly, C., Cl\u00e9ry, P.-F., Faivre-Chauvet, A., Bourgeois, M., Gu\u00e9rard, F., Haddad, F., Barbet, J., Ch\u00e9rel, M., Kraeber-Bodere, F., and Carlier, T. (2016). Immuno-PET for Clinical Theranostic Approaches. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18010057"},{"key":"ref_8","unstructured":"Rolfe, G., Freshwater, D., and Jasper, M. (2001). Critical Reflection for Nursing and the Helping Professions: A User\u2019s Guide, Palgrave."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.3389\/fimmu.2019.01945","article-title":"Editorial: Immunotherapy in Multiple Myeloma","volume":"10","author":"Giuliani","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/leu.2017.60","article-title":"Monoclonal antibody therapy in multiple myeloma","volume":"31","author":"Touzeau","year":"2017","journal-title":"Leukemia"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): A randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"New Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1080\/17474086.2018.1456331","article-title":"Anti-CD38 and anti-SLAMF7: The future of myeloma immunotherapy","volume":"11","author":"Zamagni","year":"2018","journal-title":"Expert Rev. Hematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/leu.2015.223","article-title":"Monoclonal antibodies in the treatment of multiple myeloma: Current status and future perspectives","volume":"30","author":"Lonial","year":"2015","journal-title":"Leukemia"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3389\/fimmu.2018.01228","article-title":"Daratumumab for the Treatment of Multiple Myeloma","volume":"9","author":"Plesner","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1177\/1060028016642786","article-title":"Immunotherapy","volume":"50","author":"Afifi","year":"2016","journal-title":"Ann. Pharmacother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2017-06-740944","article-title":"CD38 antibodies in multiple myeloma: Back to the future","volume":"131","author":"Richardson","year":"2018","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40262-012-0027-4","article-title":"Pharmacokinetics, Pharmacodynamics and Physiologically-Based Pharmacokinetic Modelling of Monoclonal Antibodies","volume":"52","author":"Dostalek","year":"2013","journal-title":"Clin. Pharm."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2165\/11531280-000000000-00000","article-title":"Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies","volume":"49","author":"Keizer","year":"2010","journal-title":"Clin. Pharm."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/psp4.12139","article-title":"Model-Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti\u2013PD-1 Monoclonal Antibody in Advanced Solid Tumors","volume":"6","author":"Ahamadi","year":"2016","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/psp4.12143","article-title":"Model-Based Population Pharmacokinetic Analysis of Nivolumab in Patients With Solid Tumors","volume":"6","author":"Bajaj","year":"2016","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/cpt.875","article-title":"Dose Rationalization of Pembrolizumab and Nivolumab Using Pharmacokinetic Modeling and Simulation and Cost Analysis","volume":"103","author":"Ogungbenro","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s40262-016-0477-1","article-title":"Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment","volume":"56","author":"Clemens","year":"2017","journal-title":"Clin. Pharm."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/cpt.577","article-title":"Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed\/Refractory Multiple Myeloma","volume":"101","author":"Xu","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_27","first-page":"9","article-title":"CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance","volume":"9","author":"Usmani","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Mogoll\u00f3n, P., D\u00edaz-Tejedor, A., Algar\u00edn, E., Pa\u00edno, T., Garayoa, M., and Ocio, E.M. (2019). Biological Background of Resistance to Current Standards of Care in Multiple Myeloma. Cells, 8.","DOI":"10.3390\/cells8111432"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.3389\/fimmu.2018.02749","article-title":"Promises and Pitfalls in the Use of PD-1\/PD-L1 Inhibitors in Multiple Myeloma","volume":"9","author":"Oliva","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2016-08-731885","article-title":"Targeting the PD-1\/PD-L1 axis in multiple myeloma: A dream or a reality?","volume":"129","author":"Rosenblatt","year":"2017","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/leu.2012.213","article-title":"Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma","volume":"27","author":"Tamura","year":"2012","journal-title":"Leukemia"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.3389\/fimmu.2018.02431","article-title":"Update on PD-1\/PD-L1 Inhibitors in Multiple Myeloma","volume":"9","author":"Jelinek","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.3389\/fimmu.2018.02204","article-title":"Checkpoint Inhibition in Myeloma: Opportunities and Challenges","volume":"9","author":"Costa","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1038\/leu.2015.79","article-title":"PD-L1\/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma","volume":"29","author":"Paiva","year":"2015","journal-title":"Leukemia"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1111\/bjh.15888","article-title":"Phase 1b trial of pembrolizumab monotherapy for relapsed\/refractory multiple myeloma: KEYNOTE-013","volume":"186","author":"Ribrag","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1111\/bjh.15946","article-title":"Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: Phase I KEYNOTE -023 study","volume":"186","author":"Mateos","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1016\/S2352-3026(19)30109-7","article-title":"Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): A randomised, open-label, phase 3 trial","volume":"6","author":"Usmani","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e459","DOI":"10.1016\/S2352-3026(19)30110-3","article-title":"Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): A randomised, open-label, phase 3 trial","volume":"6","author":"Mateos","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e439","DOI":"10.1016\/S2352-3026(19)30149-8","article-title":"The future of checkpoint inhibition in multiple myeloma?","volume":"6","author":"Costello","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13045-016-0345-3","article-title":"T cells in multiple myeloma display features of exhaustion and senescence at the tumor site","volume":"9","author":"Thangavadivel","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00432-018-2807-1","article-title":"Clinical and biological characteristics of myeloma patients influence response to elotuzumab combination therapy","volume":"145","author":"Danhof","year":"2018","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1182\/blood-2016-01-694604","article-title":"Randomized phase 2 study: Elotuzumab plus bortezomib\/dexamethasone vs bortezomib\/dexamethasone for relapsed\/refractory MM","volume":"127","author":"Jakubowiak","year":"2016","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/blood-2016-03-703439","article-title":"CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma","volume":"128","author":"Nijhof","year":"2016","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/ejh.13046","article-title":"Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis","volume":"100","author":"Pick","year":"2018","journal-title":"Eur. J. Haematol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1182\/blood-2018-99-113737","article-title":"CD38 Expression Levels on Myeloma Cells and the Frequency of Circulating CD38-Positive Treg Cells Are Associated with the Response to Daratumumab in Multiple Myeloma","volume":"132","author":"Kitadate","year":"2018","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.1182\/blood-2018-99-117441","article-title":"Immune Mediated Mechanisms of Resistance to Daratumumab","volume":"132","author":"Viola","year":"2018","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrc.2016.36","article-title":"Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy","volume":"16","author":"Topalian","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1182\/blood.V126.23.4222.4222","article-title":"Target-Mediated Drug Disposition of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma after Prior Proteasome Inhibitors and Immunomodulatory Drugs: A Population Pharmacokinetic Analysis","volume":"126","author":"Yan","year":"2015","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s40262-019-00748-2","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors","volume":"58","author":"Centanni","year":"2019","journal-title":"Clin. Pharm."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1517\/17425255.2012.643868","article-title":"Monoclonal antibodies: What are the pharmacokinetic and pharmacodynamic considerations for drug development?","volume":"8","author":"Deng","year":"2012","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"859","DOI":"10.4161\/mabs.28965","article-title":"Comparative clinical pharmacokinetics of antibody-drug conjugates in first-in-human Phase 1 studies","volume":"6","author":"Deslandes","year":"2014","journal-title":"mAbs"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/cpt.1211","article-title":"Tumor Drug Penetration Measurements Could Be the Neglected Piece of the Personalized Cancer Treatment Puzzle","volume":"106","author":"Bartelink","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1158\/1078-0432.CCR-18-0580","article-title":"The Long Neglected Player: Modeling Tumor Uptake to Guide Optimal Dosing","volume":"24","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41467-017-00296-y","article-title":"Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing","volume":"8","author":"Rasche","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Rasche, L., Kort\u00fcm, K.M., Raab, M.S., and Weinhold, N. (2019). The Impact of Tumor Heterogeneity on Diagnostics and Novel Therapeutic Strategies in Multiple Myeloma. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20051248"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1007\/s12325-018-0815-9","article-title":"Pharmacokinetics and Exposure\u2013Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma","volume":"35","author":"Xu","year":"2018","journal-title":"Adv. Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1182\/blood.V126.23.1849.1849","article-title":"Generation and Characterization of Microvesicles after Daratumumab Interaction with Myeloma Cells","volume":"126","author":"Chillemi","year":"2015","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"7498","DOI":"10.1158\/1078-0432.CCR-17-2027","article-title":"Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab","volume":"23","author":"Krejcik","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1182\/blood-2011-06-360552","article-title":"A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma","volume":"120","author":"Zonder","year":"2012","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"333","DOI":"10.4155\/tde.10.91","article-title":"Monoclonal antibody dose determination and biodistribution into solid tumors","volume":"2","author":"Beckman","year":"2011","journal-title":"Ther. Deliv."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1208\/s12248-018-0257-y","article-title":"Individualized Dosing of Therapeutic Monoclonal Antibodies\u2014A Changing Treatment Paradigm?","volume":"20","author":"Strik","year":"2018","journal-title":"AAPS J."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Thomas, V.A., and Balthasar, J.P. (2019). Understanding Inter-Individual Variability in Monoclonal Antibody Disposition. Antibodies, 8.","DOI":"10.3390\/antib8040056"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMp1803602","article-title":"Immunotherapy Combinations in Multiple Myeloma\u2014Known Unknowns","volume":"379","author":"Gormley","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13073-016-0369-x","article-title":"Approaches to modernize the combination drug development paradigm","volume":"8","author":"Day","year":"2016","journal-title":"Genome Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejca.2020.01.011","article-title":"The cost of cancer in Europe 2018","volume":"129","author":"Hofmarcher","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/s41571-018-0052-9","article-title":"To all involved\u2014we have a problem","volume":"15","author":"Romero","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/imj.13652","article-title":"Dealing with the spiralling price of medicines: Issues and solutions","volume":"48","author":"Ma","year":"2018","journal-title":"Intern. Med. J."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1001\/jamaoncol.2016.4166","article-title":"Assessment of Overall Survival, Quality of Life, and Safety Benefits Associated With New Cancer Medicines","volume":"3","author":"Iliopoulos","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_71","first-page":"135","article-title":"Theranostic Outcomes in Clinical Practice of Oncology: What, So What, Now What? What\u2019s More","volume":"34","author":"Turner","year":"2019","journal-title":"Cancer Biother. Radiopharm"},{"key":"ref_72","first-page":"936","article-title":"Challenges and shifting paradigms in clinical trials in oncology: The case for immunological and targeted therapies","volume":"13","author":"Ricaurte","year":"2019","journal-title":"Ecancermedicalscience"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.2217\/fon-2016-0504","article-title":"End points and statistical considerations in immuno-oncology trials: Impact on multiple myeloma","volume":"13","author":"Hoering","year":"2017","journal-title":"Future Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/s41571-019-0169-5","article-title":"The beginning of the end for conventional RECIST\u2014novel therapies require novel imaging approaches","volume":"16","author":"Gerwing","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/nrclinonc.2017.88","article-title":"Monitoring immune-checkpoint blockade: Response evaluation and biomarker development","volume":"14","author":"Nishino","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3389\/fonc.2019.00699","article-title":"Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives","volume":"9","author":"Romano","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/s41408-017-0028-5","article-title":"MRD in multiple myeloma: More questions than answers?","volume":"7","author":"Moreau","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_79","first-page":"1379","article-title":"Immuno-PET: A Navigator in Monoclonal Antibody Development and Applications","volume":"12","author":"Visser","year":"2007","journal-title":"Oncology"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1080\/10428194.2017.1337115","article-title":"Overcoming multiple myeloma drug resistance in the era of cancer \u2018omics\u2019","volume":"59","author":"Guang","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1007\/s00259-016-3458-6","article-title":"ImmunoPET to help stratify patients for targeted therapies and to improve drug development","volume":"43","author":"Bailly","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1021\/acs.chemrev.9b00738","article-title":"ImmunoPET: Concept, Design, and Applications","volume":"120","author":"Wei","year":"2020","journal-title":"Chem. Rev."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/jlcr.3605","article-title":"89Zr-ImmunoPET companion diagnostics and their impact in clinical drug development","volume":"61","author":"McKnight","year":"2018","journal-title":"J. Label. Compd. Radiopharm."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"216","DOI":"10.2967\/jnumed.117.196063","article-title":"Preclinical Development of CD38-Targeted [89Zr]Zr-DFO-Daratumumab for Imaging Multiple Myeloma","volume":"59","author":"Ghai","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1182\/blood-2017-09-807263","article-title":"Copper 64\u2013labeled daratumumab as a PET\/CT imaging tracer for multiple myeloma","volume":"131","author":"Caserta","year":"2018","journal-title":"Blood"},{"key":"ref_86","first-page":"203","article-title":"Preclinical development and First-in-human imaging of 89Zr-Daratumumab for CD38 targeted imaging of myeloma","volume":"60","author":"Ulaner","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1053\/j.seminhematol.2018.02.009","article-title":"Functional Imaging Methods for Assessment of Minimal Residual Disease in Multiple Myeloma: Current Status and Novel ImmunoPET Based Methods","volume":"55","year":"2018","journal-title":"Semin. Hematol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1148\/radiol.2020192621","article-title":"CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging","volume":"295","author":"Ulaner","year":"2020","journal-title":"Radiology"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Bailly, C., Bodet-Milin, C., Bourgeois, M., Gouard, S., Ansquer, C., Barbaud, M., S\u00e9bille, J.-C., Ch\u00e9rel, M., Kraeber-Bodere, F., and Carlier, T. (2019). Exploring Tumor Heterogeneity Using PET Imaging: The Big Picture. Cancers, 11.","DOI":"10.3390\/cancers11091282"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1038\/s41591-018-0255-8","article-title":"89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer","volume":"24","author":"Bensch","year":"2018","journal-title":"Nat. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1038\/s41467-018-07131-y","article-title":"Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer","volume":"9","author":"Niemeijer","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/clpt.2010.12","article-title":"Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer","volume":"87","author":"Dijkers","year":"2010","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1007\/s00259-015-3025-6","article-title":"Tumour targeting and radiation dose of radioimmunotherapy with (90)Y-rituximab in CD20+ B-cell lymphoma as predicted by (89)Zr-rituximab immuno-PET: Impact of preloading with unlabelled rituximab","volume":"42","author":"Muylle","year":"2015","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"902","DOI":"10.2967\/jnumed.118.214726","article-title":"Immuno-PET Imaging to Assess Target Engagement: Experience from 89Zr-Anti-HER3 mAb (GSK2849330) in Patients with Solid Tumors","volume":"60","author":"Oordt","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Bailly, C., Gouard, S., Gu\u00e9rard, F., Chalopin, B., Carlier, T., Faivre-Chauvet, A., Sa\u00ebc, P.R.-L., Bourgeois, M., Chouin, N., and Rbah-Vidal, L. (2019). What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between 89Zr- and 64Cu-Labeled Anti-CD138 in a Preclinical Syngeneic Model. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20102564"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1158\/0008-5472.CAN-17-1958","article-title":"Fc-Mediated Anomalous Biodistribution of Therapeutic Antibodies in Immunodeficient Mouse Models","volume":"78","author":"Sharma","year":"2018","journal-title":"Cancer Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.bone.2015.04.004","article-title":"A review of current murine models of multiple myeloma used to assess the efficacy of therapeutic agents on tumour growth and bone disease","volume":"77","author":"Chantry","year":"2015","journal-title":"Bone"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s10585-007-9125-3","article-title":"Syndecan-1: A dynamic regulator of the myeloma microenvironment","volume":"25","author":"Sanderson","year":"2007","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1016\/S1470-2045(17)30189-4","article-title":"Role of 18F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: A consensus statement by the International Myeloma Working Group","volume":"18","author":"Cavo","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1158\/0008-5472.CAN-16-2523","article-title":"Whither radioimmunotherapy: To be or not to be?","volume":"77","author":"Green","year":"2017","journal-title":"Cancer Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/s00259-011-2008-5","article-title":"Biodistribution, radiation dosimetry and scouting of 90Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin\u2019s lymphoma using 89Zr-ibritumomab tiuxetan and PET","volume":"39","author":"Rizvi","year":"2012","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.1200\/JCO.2008.17.2015","article-title":"Phase III Trial of Consolidation Therapy With Yttrium-90\u2013Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma","volume":"26","author":"Morschhauser","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2002.11.017","article-title":"Treatment With Ibritumomab Tiuxetan Radioimmunotherapy in Patients With Rituximab-Refractory Follicular Non-Hodgkin\u2019s Lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.remn.2016.05.004","article-title":"Radioinmunoterapia en el linfoma no Hodgkin, posicionamiento, seguridad y eficacia de 90Y-ibritumomab. Experiencia y seguimiento a los 10 a\u00f1os","volume":"36","author":"Beneit","year":"2017","journal-title":"Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1200\/JCO.2011.41.1553","article-title":"90Yttrium-Ibritumomab-Tiuxetan as First-Line Treatment for Follicular Lymphoma: 30 Months of Follow-Up Data From an International Multicenter Phase II Clinical Trial","volume":"31","author":"Scholz","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1016\/S2352-3026(16)30188-0","article-title":"Radioimmunotherapy of lymphoma: An underestimated therapy option","volume":"4","author":"Hohloch","year":"2017","journal-title":"Lancet Haematol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1200\/JCO.2009.26.8748","article-title":"Radioimmunotherapy of Lymphoma: A Treatment Approach Ahead of Its Time or Past Its Sell-By Date?","volume":"28","author":"Illidge","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1053\/j.semnuclmed.2010.01.002","article-title":"Cancer Therapy with Alpha-Emitters Labeled Peptides","volume":"40","author":"Dadachova","year":"2010","journal-title":"Semin. Nucl. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3389\/fmed.2015.00076","article-title":"Single-Dose Anti-CD138 Radioimmunotherapy: Bismuth-213 is More Efficient than Lutetium-177 for Treatment of Multiple Myeloma in a Preclinical Model","volume":"2","author":"Fichou","year":"2015","journal-title":"Front. Med."},{"key":"ref_110","first-page":"S166","article-title":"Efficacy of Astatine-211 Radioimmunotherapy of Multiple Myeloma Using an Anti-mCD138 Monoclonal Antibody in a Syngeneic Murine Model","volume":"45","author":"Gouard","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/j.nucmedbio.2014.02.008","article-title":"Comparative analysis of multiple myeloma treatment by CD138 antigen targeting with bismuth-213 and Melphalan chemotherapy","volume":"41","author":"Gouard","year":"2014","journal-title":"Nucl. Med. Boil."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.2967\/jnumed.112.111997","article-title":"213Bi Radioimmunotherapy with an Anti-mCD138 Monoclonal Antibody in a Murine Model of Multiple Myeloma","volume":"54","author":"Gouard","year":"2013","journal-title":"J. Nucl. Med."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"9061","DOI":"10.18632\/oncotarget.23886","article-title":"Comparison of Immuno-PET of CD138 and PET imaging with 64CuCl2 and 18F-FDG in a preclinical syngeneic model of multiple myeloma","volume":"9","author":"Bailly","year":"2018","journal-title":"Oncotarget"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/6\/1467\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:35:44Z","timestamp":1760175344000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/6\/1467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,4]]},"references-count":113,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,6]]}},"alternative-id":["cancers12061467"],"URL":"https:\/\/doi.org\/10.3390\/cancers12061467","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,4]]}}}